Clinical trials: Macular Disease
Stargardt Disease, Age-related Macular Degeneration
Phase 1 Safety Study of ALK-001 in Healthy Volunteers
This protocol is a phase 1 clinical study to assess the safety and pharmacokinetics of ALK-001 in healthy volunteers. Please contact trials@alkeus.com for any questions.
- Conditions
- Stargardt Disease, Age-related Macular Degeneration, Other Retinal Dystrophies
- Trial name
- NCT02230228
- Testing
- ALK-001 (No generic name)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alkeus Pharmaceuticals, Inc.
Age-related Macular Degeneration (AMD)
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs.
- Trial name
- NCT05110209
- Testing
- Aflibercept, Ranibizumab, Bevacizumab
- Where
- United States
- Volunteers
- 331,541 people
- Sponsor
- Novartis Pharmaceuticals
Stargardt Disease, Stargardt Macular Dystrophy
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye.
- Conditions
- Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
- Trial name
- DEVOTE (NCT07734064)
- Testing
- ASP2020
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Retinal Vein Occlusion, Macular Oedema
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion
The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received…
- Trial name
- NCT01566526
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Belgium
- Volunteers
- 26 people
- Sponsor
- Allergan
Macular Edema, Retinal Vein Occlusion
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of macular edema associated with retinal vein occlusion.
- Trial name
- NCT00168324
- Testing
- 700 µg Dexamethasone, 350 µg Dexamethasone
- Where
- 13 sites in United States, Australia and 11 more
- Volunteers
- 599 people
- Sponsor
- Allergan
Geographic Atrophy
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525613
- Testing
- APL-2
- Where
- 112 sites in United States, Australia and 12 more
- Volunteers
- 637 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Diabetes Mellitus, Macular Edema
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement…
- Trial name
- RIDE (NCT00473382)
- Testing
- Ranibizumab
- Volunteers
- 382 people
- Sponsor
- Genentech, Inc.
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in participants with atrophic macular degeneration.
- Trial name
- NCT00447954
- Testing
- High Dose NT-501 implant, Low Dose NT-501 implant
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- Neurotech Pharmaceuticals
Age-Related Macular Degeneration
Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
Palomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation.
- Trial name
- P52901 (NCT01033721)
- Testing
- Palomid 529
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Paloma Pharmaceuticals, Inc.
Age-related Macular Degeneration
A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration
A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.
- Trial name
- NCT04151212
- Testing
- BAT5906 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Bio-Thera Solutions
Geographic Atrophy
Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride
The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration.
- Trial name
- SEATTLE (NCT01802866)
- Testing
- ACU-4429
- Where
- United States
- Volunteers
- 508 people
- Sponsor
- Kubota Vision Inc.
Visual Impairment, Macular Edema
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator…
- Conditions
- Visual Impairment, Macular Edema, Central Retinal Vein Occlusion
- Trial name
- COMRADE-C (NCT01396083)
- Testing
- Ranibizumab
- Where
- 64 sites in Germany, Hungary and 2 more
- Volunteers
- 243 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
Visudyne® in Occult (VIO)
The purpose of this study is to demonstrate that Visudyne therapy in patients who have occult with no classic subfoveal choroidal neovascularization (CNV) lesions will, with an acceptable safety profile, significantly reduce the…
- Trial name
- NCT00121407
- Testing
- Visudyne for injection
- Volunteers
- 364 people
- Sponsor
- QLT Inc.
Diabetic Retinopathy, Age Related Macular Degeneration
Retinal Care Data Repository
The Retinal Care Data Repository's primary objective is to make data available for Retinal Care to develop algorithms that improve the care of people with retinal diseases.
- Trial name
- NCT04794907
- Testing
- Observation
- Volunteers
- 1,000 people
- Sponsor
- Retinal Care Inc.
Age-Related Macular Degeneration (AMD)
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment.
- Trial name
- NCT00354445
- Testing
- pegaptanib sodium (Macugen)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Eyetech Pharmaceuticals
Macular Degeneration
Long-Term Efficacy in AMD of Rheopheresis in North America
The purpose of these studies are to evaluate the effect on vision in subjects with AMD who received active and placebo treatment in the MIRA-1 study.
- Trial name
- NCT00380172
- Testing
- Rheopheresis blood filtration
- Where
- 9 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- OccuLogix
Eye Diseases, Macular Degeneration
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis™ in patients with…
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration
- Trial name
- NCT02543229
- Testing
- OPT-302, Lucentis™
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Opthea Limited
Dry Age-related Macular Degeneration
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- NCT04566445
- Testing
- GT005
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 255 people
- Sponsor
- Gyroscope Therapeutics Limited
nAMD
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
The goal of this clinical trial is to evaluate the safety and efficacy of IVB103 injection in subjects with nAMD.
- Trial name
- NCT06737354
- Testing
- IVB103 Injection（Low dose）, IVB103 Injection（Intermediate dose）, IVB103 Injection（High dose）
- Where
- China
- Volunteers
- 18 people
- Sponsor
- InnoVec Biotherapeutics Inc.
Macular Degeneration
A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
A study to evaluate pazopanib tablets in male and female adults of non-child bearing potential with subfoveal CNV due to neovascular AMD. The goal is to assess safety and how well the subjects tolerate the drug.
- Trial name
- NCT01154062
- Testing
- Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline